Reduced expression of SOX7 in ovarian cancer: A novel tumor suppressor through the Wnt/β-catenin signaling pathway

Journal of Ovarian Research

Volumn 7, Issue 1, 2014, Pages

  Liu, Huidi ^a,b,d   Yan, Zi Qiao ^a   Li, Bailiang ^a   Yin, Si Yuan ^a   Sun, Qiang ^a   Kou, Jun Jie ^a   Ye, Dan ^a   Ferns, Kelsey ^a,e   Liu, Hong Yu ^c   Liu, Shu Lin ^a,b,d  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b HMU UCFM Centre for Infection and Genomics   (China)

^c The First Hospital of Qiqihaer City   (China)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Ovarian cancer; SOX7; Tumor suppressor; Wnt catenin signaling pathway

Indexed keywords

BETA CATENIN; CYCLIN D1; CYCLOOXYGENASE 2; TRANSCRIPTION FACTOR SOX7; TUMOR MARKER; WNT PROTEIN; SOX7 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX;

ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; CYSTADENOCARCINOMA; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; OVARY CANCER; OVARY CARCINOMA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ADULT; AGED; CANCER GRADING; DISEASE COURSE; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; INFORMATION PROCESSING; METABOLISM; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE; WNT SIGNALING PATHWAY; YOUNG ADULT;

ADULT; AGED; CELL LINE, TUMOR; CYCLIN D1; CYCLOOXYGENASE 2; DATASETS AS TOPIC; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; OVARIAN NEOPLASMS; SOXF TRANSCRIPTION FACTORS; WNT SIGNALING PATHWAY; YOUNG ADULT;

EID: 84908150781     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/s13048-014-0087-1     Document Type: Article

References (30)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300.
2. Partridge EE, Barnes MN: Epithelial ovarian cancer: prevention, diagnosis, and treatment. CA Cancer J Clin 1999, 49 (5):297-320.
3. Vrabie CD, Petrescu A, Waller M, Dina I: Clinical factors and biomarkers in ovarian tumors development. Rom J Morphol Embryol 2008, 49(3):327-338.
4. Ovarian cancer: A look at common myths and facts. Mayo Clin Womens Healthsource 2009, 13(9):1-2.
5. Stovall DB, Cao P, Sui G: SOX7: From a developmental regulator to an emerging tumor suppressor. Histol Histopathol 2013, 29(4):439-445.
6. Long F, Wang X, Fang S, Xu Y, Sun K, Chen S, Xu R: A potential relationship among beta-defensins haplotype, SOX7 duplication and cardiac defects. PLoS One 2013, 8(8):e72515.
7. Costa G, Mazan A, Gandillet A, Pearson S, Lacaud G, Kouskoff V: SOX7 regulates the expression of VE-cadherin in the haemogenic endothelium at the onset of haematopoietic development. Development 2012, 139(9):1587-1598.
8. Francois M, Koopman P, Beltrame M: SoxF genes: Key players in the development of the cardio-vascular system. Int J Biochem Cell Biol 2010, 42(3):445-448.
9. Herpers R, van de Kamp E, Duckers HJ, Schulte-Merker S: Redundant roles for sox7 and sox18 in arteriovenous specification in zebrafish. Circ Res 2008, 102(1):12-15.
10. Takash W, Canizares J, Bonneaud N, Poulat F, Mattei MG, Jay P, Berta P: SOX7 transcription factor: sequence, chromosomal localisation, expression, transactivation and interference with Wnt signalling. Nucleic Acids Res 2001, 29 (21):4274-4283.
11. Fan R, Zhang LY, Wang H, Yang B, Han T, Zhao XL, Wang W, Wang XQ, Lin GW: Methylation of the CpG island near SOX7 gene promoter is correlated with the poor prognosis of patients with myelodysplastic syndrome. Tohoku J Exp Med 2012, 227(2):119-128.
12. Li B, Ge Z, Song S, Zhang S, Yan H, Huang B, Zhang Y: Decreased expression of SOX7 is correlated with poor prognosis in lung adenocarcinoma patients. Pathol Oncol Res 2012, 18 (4):1039-1045.
13. Stovall DB, Wan M, Miller LD, Cao P, Maglic D, Zhang Q, Stampfer MR, Liu W, Xu J, Sui G: The regulation of SOX7 and its tumor suppressive role in breast cancer. Am J Pathol 2013, 183(5):1645-1653.
14. Guo L, Zhong D, Lau S, Liu X, Dong XY, Sun X, Yang VW, Vertino PM, Moreno CS, Varma V, Dong JT, Zhou W: Sox7 Is an independent checkpoint for beta-catenin function in prostate and colon epithelial cells. Mol Cancer Res 2008, 6(9):1421-1430.
15. Chan DW, Mak CS, Leung TH, Chan KK, Ngan HY: Down-regulation of Sox7 is associated with aberrant activation of Wnt/b-catenin signaling in endometrial cancer. Oncotarget 2012, 3(12):1546-1556.
16. Clapper ML, Coudry J, Chang WC: beta-catenin-mediated signaling: a molecular target for early chemopreventive intervention. Mutat Res 2004, 555(1-2):97-105.
17. Zhou X, Huang SY, Feng JX, Gao YY, Zhao L, Lu J, Huang BQ, Zhang Y: SOX7 is involved in aspirin-mediated growth inhibition of human colorectal cancer cells. World J Gastroenterol 2011, 17(44):4922-4927.
18. Zhang Y, Huang S, Dong W, Li L, Feng Y, Pan L, Han Z, Wang X, Ren G, Su D, Huang B, Lu J: SOX7, down-regulated in colorectal cancer, induces apoptosis and inhibits proliferation of colorectal cancer cells. Cancer Lett 2009, 277(1):29-37.
19. Hayano T, Garg M, Yin D, Sudo M, Kawamata N, Shi S, Chien W, Ding LW, Leong G, Mori S, Xie D, Tan P, Koeffler HP: SOX7 is down-regulated in lung cancer. J Exp Clin Cancer Res 2013, 32:17.
20. Katoh M: Expression of human SOX7 in normal tissues and tumors. Int J Mol Med 2002, 9(4):363-368.
21. Da Huang W, Sherman BT, Lempicki RA: Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009, 37(1):1-13.
22. Da Huang W, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4(1):44-57.
23. Benjamini YHY: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995, 57:289-300.
24. King ER, Tung CS, Tsang YT, Zu Z, Lok GT, Deavers MT, Malpica A, Wolf JK, Lu KH, Birrer MJ, Mok SC, Gershenson DM, Wong KK: The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer. Am J Surg Pathol 2011, 35(6):904-912.
25. McCluggage WG: Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 2011, 43(5):420-432.
26. Arend RC, Londono-Joshi AI, Straughn JM Jr, Buchsbaum DJ: The Wnt/beta-catenin pathway in ovarian cancer: a review. Gynecol Oncol 2013, 131(3):772-779.
27. Basu M, Roy SS: Wnt/beta-catenin pathway is regulated by PITX2 homeodomain protein and thus contributes to the proliferation of human ovarian adenocarcinoma cell, SKOV-3. J Biol Chem 2013, 288(6):4355-4367.
28. Wu GG, Li WH, He WG, Jiang N, Zhang GX, Chen W, Yang HF, Liu QL, Huang YN, Zhang L, Zhang T, Zeng XC: Mir-184 post-transcriptionally regulates SOX7 expression and promotes cell proliferation in human hepatocellular carcinoma. PLoS One 2014, 9(2):e88796.
29. Zhong WD, Qin GQ, Dai QS, Han ZD, Chen SM, Ling XH, Fu X, Cai C, Chen JH, Chen XB, Lin ZY, Deng YH, Wu SL, He HC, Wu CL: SOXs in human prostate cancer: implication as progression and prognosis factors. BMC Cancer 2012, 12:248.
30. Wang C, Guo Y, Wang J, Min Z: The suppressive role of SOX7 in hepatocarcinogenesis. PLoS One 2014, 9(5):e97433.